Novo Nordisk Metsera bid rejected over FTC antitrust risk

When Novo Nordisk and Pfizer's final identical bids both reached $86.25/share, Metsera's board chose Pfizer based on deal-closing probability, illustrating how antitrust risk functions as a valuation discount in competitive auctions.